Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders

Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Marketing Authorization in EU

Shots:

  • The EMA’s CHMP has recommended marketing authorization of Amsparity, a biosimilar referencing AbbVie’s Humira
  • Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults and a 20 mg pre-filled syringe and 40 mg/0.8 mL vial for children. Amsparity showed high bio-similarity data in terms of quality, safety and efficacy to Humira
  • Amsparity is mAb targeting TNFα, act by blocking its interaction with the p55 and p75 cell-surface TNF receptors and is indicated for multiple autoimmune disorders including RA, AS, CD

Click here to­ read full press release/ article | Ref: EMA | Image: STAT